Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

rded.

Research and development expenses for the first quarter ended March 31, 2010 were $6.4 million, compared to $1.7 million in the corresponding period of 2009. The increased research and development expenses resulted from OncoGenex's contribution to the OGX-011 Phase III clinical trials in the amount of $1.9 million and manufacturing costs in the amount of $2.8 million, the latter of which is reimbursable from Teva.

General and administrative expenses for the first quarter ended March 31, 2010 were $1.4 million, compared to $0.8 million in the corresponding period of 2009. The increase in the first quarter of 2010 was due mainly to higher employee expenses including severance charges, professional fees for legal and accounting services, employee recruitment costs and stock based compensation expense.

The net loss for the first quarter ended March 31, 2010 was $3.0 million, compared to $2.4 million in the corresponding period of 2009.

The Company had $47.6 million in cash, cash equivalents and short-term investments as of March 31, 2010, compared to $64.6 million at December 31, 2009. The decrease in cash, cash equivalents, and short-term investments is primarily due to costs incurred in the first quarter of 2010 relating to the OGX-011 development plan, and the $10 million payment made to Isis in the first quarter of 2010, which was included in accounts payable as a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
(Date:7/10/2014)... Hall effect in bilayer graphene and shown that this ... electric field. , The fractional quantum Hall effect, ... are exposed to large magnetic fields, is a striking ... behave as a single system. However, while the basic ... of this collective behavior remain not well understood, in ...
(Date:7/10/2014)... new alliance will see the two universities and NPL ... with business and industry and their complementary academic strengths., ... help to shape the scientific priorities of the UK. ... up to 300 high-calibre PhD students, will provide a ... NPL, the potential of the Laboratory will be grown ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... CEPH ) will hold a public memorial service to ... CEO on February 1, 2011, at 6:00 p.m. at The Franklin ... Dr. Baldino founded Cephalon in 1987 and led the company ... biotechnology companies in the world. He was a recognized pioneer in ...
... 24, 2011 Myriant Technologies, Inc. (Myriant), ... renewable bio-based chemicals, announced today the closing ... from PTT Chemical Group (PTT Chemical), Thailand,s ... http://photos.prnewswire.com/prnh/20091021/NE96331LOGO) Myriant will utilize the ...
... 2011 Cardium Therapeutics (NYSE Amex: CXM ... on December 2, 2010 has been accepted by the ... ) As previously reported, a communication from ... that the company was considered to be noncompliant with ...
Cached Biology Technology:Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2Myriant Technologies, Inc. Announces US$60 Million Strategic Equity Investment From PTT Chemical Group 2Myriant Technologies, Inc. Announces US$60 Million Strategic Equity Investment From PTT Chemical Group 3Cardium's Exchange Listing Compliance Plan Accepted by NYSE Amex 2Cardium's Exchange Listing Compliance Plan Accepted by NYSE Amex 3Cardium's Exchange Listing Compliance Plan Accepted by NYSE Amex 4
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... San Diego Supercomputer Center (SDSC) at the University ... researchers worldwide unravel the enigmas of phylogenetics, the ... on the planet. The CIPRES Science Gateway ... created by SDSC researchers, allows these studies to ...
... that comes the threat of West Nile virus. Tom Hobman, ... in the Faculty of Medicine & Dentistry, is making every ... , West Nile virus infections often result in flu-like ... show no symptoms at all. But a significant percentage of ...
... new fossil find from the chalk beds of the Franconian ... predatory dinosaur reveals clear traces of fluffy plumage. It also ... The fossil of the fledgling saurian, probably newly hatched ... First of all, juveniles are extremely rare in the dinosaur ...
Cached Biology News:SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 2SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 3Researchers moving towards ending threat of West Nile virus 2Feathered saurians -- downy dinosaur discovered 2
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... produces a powerful, stable output from 215-400 nm. ... are available, providing a wavelength range of 190-400 ...
... situ detection of apoptosis and mitochondrial membrane ... an early indication of the initiation of ... as a collapse in the electrochemical gradient ... the change in the membrane potential (YD). ...
... The NOVOstar is an exciting product ... Previously, cell-based assays required the use of ... accessibility for scientists in the assay development ... necessary for cell-based assays as well as ...
... One can operate as a Voltage Clamp, as ... Clamp in electrophysiology research applications. Performance in any ... equipment. • This amazing ... in the capabilities of Digital Signal Processing (DSP) ...
Biology Products: